Why the study?
What are the rates, management, and outcomes of rivaroxaban-related bleeding in real-world daily care patients?
What are the rates, management, and outcomes of rivaroxaban-related bleeding in real-world daily care patients?
In real-world practice, rivaroxaban-related major bleeding rates are relatively low and outcomes appear comparable to or better than historical vitamin K antagonist bleeding.
No takes yet. Share an insight, caveat, or question.
Supports low major bleeding rates with rivaroxaban in real-world settings; extends prior evidence but leaves randomized comparisons open.
Beyer‐Westendorf et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: